Antonio Llombart, MD @harnaulleida @wearemedsir #SABCS #B...

Antonio Llombart, MD @harnaulleida @wearemedsir #SABCS #BreastCancer #Cancer #Research PARSIFAL a Multicenter, Randomized, Open-Label, Phase II Trial
SABCS Photo

SABCS
2 years 79 Views
Category:
Description:

Antonio Llombart-Cussac, MD, Ph.D.  founding partner of Medica Scientia Innovation Research (MedSIR) and the Hospital Arnau de Vilanova speaks about the SABCS 2020 Abstract - Palbociclib in Combination with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR+/HER2- Metastatic Breast Cancer: Detailed Safety Analysis from a Multicenter, Randomized, Open-Label, Phase II Trial (PARSIFAL).


Abstract -
The PARSIFAL study was an international, randomized, open-label phase II trial in patients with endocrine-sensitive, estrogen receptor-positive (ER[+]) and human epidermal growth factor receptor-2-negative (HER2[-]) metastatic breast cancer (HER2[-]) in patients with endocrine-sensitive, estrogen receptor-positive (ER[+]) and human epidermal growth factor receptor-2-negative (HER2[-]) metastatic breast cancer as initial therapy (MBC). Dr. José Manuel Pérez-García of the International Breast Cancer Center (IBCC), Quirón Group (Barcelona, Spain) will present at SABCS 2020 the findings of a comprehensive analysis of the safety and tolerability profile of the two combinations of regimens, with a particular focus on venous thromboembolism. The PARSIFAL study findings could help doctors decide what is the best combination of medicines to use in the treatment of this subtype of advanced breast cancer patients.